Production, recovery, and purification of recombinant 503 antigen of Leishmania infantum chagasi using expanded bed adsorption chromatography

• Autor(a) principal: Santos, Everaldo Silvino dos
• Data de Publicação: 2014
• Outros Autores: Sousa Junior, Francisco Canindé de, Vaz, Michelle Rossana Ferreira, Padilha, Carlos Eduardo de Araújo, Martins, Daniella Regina Arantes, Macedo, Gorete Ribeiro de
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFRN
• Texto Completo: https://repositorio.ufrn.br/handle/123456789/32543
• topic: Visceral Leishmaniasis; Leishmaniasis; Elution Condition; Batch Adsorption Experiment; Leishmania Infantum

Visceral leishmaniasis, a disease caused by Leishmania infantum chagasi, represents a major public health problem in many areas of the world. Despite the considerable effort, there is no effective and safe vaccine for human use [1]. Some authors have reported that as much as 50% of overall costs in the biotechnology industries are related to downstream processing. Thus, the development of new and economically advantageous purification methods is a challenge [2]. Expanded bed adsorption (EBA) is an innovative chromatography technology that allows the adsorption of target proteins directly from unclarified feedstock. EBA technology combines solid-liquid separation with an adsorption step in a single-unit operation, aiming at increased overall yield, reduced operational time, and less capital investment and consumables [3,4]. Thus, the aim of this work was to purify the 503 antigen of Leishmania i. chagasi directly from crude feedstock using EBA chromatography